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Eﬀect of a Probiotic on Prevention of Diarrhea and Clostridium
diﬃcile and Clostridium perfringens Shedding in Foals
A. Schoster, H.R. Staempﬂi, M. Abrahams, M. Jalali, J.S. Weese, and L. Guardabassi
Background: Up to 60% of foals develop diarrhea within 6 months after birth. Preventive measures are limited but
potentially probiotics could be used.
Objective: To evaluate the eﬀect of a newly designed probiotic on the incidence of foal diarrhea in a randomized ﬁeld
trial.
Animals: Seventy-two healthy neonatal foals.
Methods: Randomized, placebo-controlled ﬁeld trial. Foals were administered a placebo or probiotic for 3 weeks and
monitored for an additional week. A total of 3 fecal samples were taken from each foal at biweekly intervals. Statistical mod-
eling was applied for comparison of incidence and duration of diarrhea and fecal shedding of Clostridium perfringens and
Clostridium diﬃcile between treatment and age groups.
Results: The overall incidence of diarrhea was 41 of 72 (59%) and did not diﬀer (P = 0.37) between treatment groups.
Foals treated with probiotics were more likely to develop diarrhea requiring veterinary intervention (P = 0.007). Age had a
signiﬁcant eﬀect on incidence of diarrhea (P < 0.001); foals 8–15 days old having the highest probability of developing diar-
rhea. Duration of diarrhea and soft feces were not signiﬁcantly diﬀerent between groups. The prevalence of C. perfringens
shedding was 55% with no diﬀerence between treatment groups (P = 0.23). The prevalence of C. diﬃcile shedding was 11%.
Conclusion and Clinical Importance: There was no beneﬁt of administering a 3-week course of probiotics, but potential
adverse eﬀects were noted. Whether the probiotics lacked a clinical eﬀect, or the choice of strains or dose was inadequate, is
unknown. Clostridial shedding was not inﬂuenced by probiotics despite in vitro activity of probiotics.
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Up to 60% of foals develop diarrhea in their ﬁrst6 months of life.1 The etiology is often undeter-
mined and could be multifactorial; however, infectious
agents, particularly bacteria such as Clostridium diﬃcile
and Clostridium perfringens could play important roles.1
Preventive measures are currently limited and novel
approaches are needed.2 Probiotics have received
increasing interest in veterinary medicine to prevent and
treat enteric disease.3–5 Probiotics exert their beneﬁcial
eﬀect through several pathways, including production
of antimicrobial compounds targeting intestinal patho-
gens and their toxins, as well as general immune stimu-
lation and colonization resistance.6 Few studies in
horses have been performed to date to evaluate the eﬃ-
cacy of probiotics in prevention or treatment of enteric
disease.4,7,8 The 2 studies on probiotic use to prevent
neonatal foal diarrhea failed to show a lack of signiﬁ-
cant eﬀect of probiotic treatment.3,9 Potential reasons
for this include the bacterial strain(s) chosen, the dose
administered, the duration of administration, and tim-
ing of administration. A 1-week treatment course was
chosen in both of the above studies but probiotics are
typically considered unable to persist in the gastrointes-
tinal tract after cessation of administration.10 Longer
periods of treatment could therefore be needed. Com-
mercial probiotic products often contain unreliable and
varying amounts of active ingredients and scientiﬁc evi-
dence supporting these formulations is lacking.11
Recently, several commercial bacterial strains (Lactoba-
cillus rhamnosus LHR 19 and SP1, L. plantarum LPAL
and BG112 and Biﬁdobacterium animalis lactis) have
been shown to inhibit growth of C. diﬃcile and
C. perfringens in vitro and to grow in the presence of
acid and bile, making them suitable for further evalua-
tion as animal probiotics.12
The objective of this study was to determine the eﬀect
of a probiotic formulation consisting of the 4 above
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described 4 Lactobacillus species and Biﬁdobacterium ani-
malis lactis on the incidence of diarrhea and prevalence
of fecal pathogen shedding in neonatal foals in a 4-week
randomized, placebo-controlled clinical ﬁeld trial.
Materials and Methods
The study was conducted as a randomized, placebo-controlled
blinded ﬁeld trial on breeding farms in Southern Ontario, Canada.
The study was conducted under approval of the Animal Use and
Care Committee of the University of Guelph (AUP 1455).
Reporting of this trial follows the CONSORT 2010
guidelines.13
Study Design
A sample size calculation was performed assuming a diarrhea
incidence of 50% in neonatal foals. A sample size of 93 animals
was calculated to detect a 20% diﬀerence and achieve a power of
0.8 with an alpha error of 0.05. Foals from 7 breeding farms were
enrolled at the time of birth with an anticipated 10–20 foals per
farm. Inclusion criteria for farms included the birth of more than
10 foals per season and willingness to participate in the study.
All foals that were born by natural delivery between March 1st
2013 and July 30th 2014 and were clinically normal at the time of
enrollment were eligible for inclusion. Determination of clinical
status was made by an experienced farm manager on each farm.
Exclusion criteria included presence of gastrointestinal disease or
illness that would preclude the administration of probiotics as
judged by the farm manager, as well as prior administration of an-
timicrobials or probiotics. No other probiotics were administered
to the foals during the study and routine farm management was
maintained.
Treatment and placebo packages were indistinguishable and
were prepared with sequentially labeled numbers for each farm by
one of the authors (AS). The treatment group of the ﬁrst package
for each farm was determined by coin toss, with subsequent pack-
ages assigned in an alternating fashion (consecutive stratiﬁed ran-
domization per farm). Farm personnel were provided with the
numbered treatment packages and instructed to assign the ﬁrst
foal born on the farm to treatment package 1 and continue in
consecutive fashion, and were so blinded to the treatment groups.
The probiotic product contained 1 9 109 colony-forming units
(cfu) of each of L. rhamnosus SP1, L. rhamnosus LRH19, L. plan-
tarum LPAL, L. plantarum BG112, and 1 9 1010 cfu of Biﬁdobac-
terium animalis lactis strain with starch added for a total weight of
2 g. The placebo product contained the starch without the bacte-
rial cultures. Both products had indistinguishable visual appear-
ance and odor. The products were distributed in individual 2 g
dose sachets for each foal. Farm personnel were instructed to mix
the contents with 10 mL of water or syrup and administer the
solution via an oral dosing syringe.
The treatments were administered once daily for 21 days start-
ing on day 3 of life. Farm personnel monitored the foals daily for
28 days. Farm personnel were instructed to record abnormal fecal
consistency (ﬁrm, soft feces, diarrhea). If diarrhea occurred, farm
personnel were instructed to record rectal temperature, appetite,
and attitude. If the farm personnel considered the clinical signs
severe enough for need of veterinary examination, the farm veteri-
narian was asked to assess the foal and decide on necessary treat-
ments. If treatments were administered, they were recorded. A
medical record sheet containing all of the above variables for each
foal was supplied.
Fecal samples were collected from foals by rectal swab at 0–2,
2–4, and 4–6 weeks of age. The exact day of sampling was decided
by farm personal. Samples were frozen at 80°C until analysis.
Bacterial Culture and Typing
Selective enrichment culture and molecular typing of
C. perfringens and C. diﬃcile was performed as previously
reported.14 Please refer to the supporting document (Appendix S1)
for further information.
Quality Control
Samples of probiotic and placebo sachets were analyzed for
their content. Serial dilutions were performed in phosphate-buf-
fered saline and inoculated onto Man-Rogosa-Sharp agar.a The
plates were incubated anaerobically for 24 hours at 37°C and
resulting colonies were counted.
Statistical Analysis
Outcomes of interest included the incidence of diarrhea, inci-
dence of soft feces, and the incidence of diarrhea severe enough to
require veterinary treatment. A generalized linear mixed model
with random eﬀects was used to examine the above outcomes of
interest and fecal shedding of Clostridia spp. in relation to the age
of the foal. A general linear mixed model was used to predict dif-
ferences in duration of diarrhea and soft feces between groups.
Farm and year were combined into 1 factor and were considered a
random eﬀect, whereas sex, treatment, and age group were consid-
ered ﬁxed eﬀects. Repeated measures were accounted for. Various
error structures were examined (ar1, arh1, toep2-3, toeph2-3, un2-
3). The best-ﬁt error structure was chosen based on the Akaike
information criterion or whether the model converged. Random
eﬀects, ﬁxed eﬀects, and their interactions with a P < 0.25 were
retained in the ﬁnal model. The correlation between a positive cul-
ture results and presence of abnormal feces was tested using the
Pearson’s correlation coeﬃcient. Analysis was conducted by a
commercial statistical software package.b Signiﬁcance was set at
P < 0.05.
Descriptive statistics were used when data were not present in
suﬃcient numbers for statistical analysis.
Results
A total of 93 foals from 7 farms met the inclusion
criteria. One farm lost all medical records and the foals
(10 in each treatment group) had to be removed from
analysis. One foal (probiotic group) sustained a trau-
matic stiﬂe injury requiring euthanasia and was
removed. This left 72 foals from 6 farms for analysis,
36 foals in each treatment group. Of the resulting 72
foals, 68 (94%) were Thoroughbreds and 4 of 72 (6%)
were Standardbreds. Twenty-six (36%) foals were
female and 46 of 72 (64%) were male. The initial plan
to enroll more than 10 foals per farm was not accom-
plished on all farms because of human error. Each farm
contributed between 4 and 20 foals. Clinical signs were
inconsistently reported and therefore removed from
analysis.
Incidence of Diarrhea and Soft Feces
The incidence of diarrhea was 41 of 72 (59%) and
soft feces were identiﬁed in 47 of 72 (65%). The distri-
bution for each treatment group is shown in Figure 1.
Age group had a signiﬁcant eﬀect on occurrence of
diarrhea (P < 0.001), with a signiﬁcantly higher
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incidence in foals between 8 and 15 days of age (Fig. 2).
All pairwise comparisons are shown in Table 1. The
factor farm/year was retained in the ﬁnal model
(P = 0.1). Sex (P = 0.06) and treatment (P = 0.37) did
not have a signiﬁcant eﬀect on incidence of diarrhea.
There was a signiﬁcant association between age and
the occurrence of soft feces (P < 0.001). Pairwise com-
parisons are shown in Table 1. The factor farm/year
was retained in the ﬁnal model (P = 0.08). Sex
(P = 0.88) and treatment (P = 0.62) did not have a sig-
niﬁcant eﬀect.
Eighteen (25%) foals had diarrhea severe enough to
require veterinary intervention of which 12 of 18 (66%)
foals were in the probiotic and 6 of 18 (33%) were in
the placebo group (Fig. 1), respectively. Placebo-treated
foals were less likely to develop diarrhea in need of vet-
erinary treatment than probiotic-treated foals (OR:
0.35, CI: 0.16–0.75, P = 0.007). There was a signiﬁcant
eﬀect of age (P < 0.001). Pairwise comparisons are
shown in Table 2. The factor farm/year was retained in
the ﬁnal model (P = 0.06). Sex (P = 0.88) did not have
a signiﬁcant eﬀect. Medical treatments of foals included
antimicrobial treatment (metronidazole, trimethoprim
sulfonamide, ceftiofur, oxytetracycline, penicillin, and
chloramphenicol) and analgesic treatment (ﬂunixin
meglumine). Additional treatments recorded were
di-tri-octahedral smectite, butylscopolamine, ranitidine,
omeprazole, and sucralfate.
Odds ratios and their conﬁdence intervals are
reported in Table 2.
Duration of Diarrhea
Duration of diarrhea ranged from 0 to 11 days in
both groups. The distribution per group is shown in
Figure 3. The factor farm/year (P = 0.19) and the inter-
action of the factor farm/year and treatment (P = 0.17)
were retained in the ﬁnal model. There was no impact
of treatment (P = 0.31) or sex (P = 0.06) on duration of
diarrhea. There was no apparent impact of treatment
(P = 0.8) or age (P = 0.2) on the occurrence of soft
feces.
Bacteriologic Cultures
A total of 178 fecal samples were collected, each foal
had at least 2 samples collected. The time prevalence
rate was 20 of 178 (11%) and 98 of 178 (55%) for
C. diﬃcile and C. perfringens, respectively. This corre-
sponded to a foal-level time prevalence rate of 20 of 72
(28%) for C. diﬃcile and 45 of 72 (63%) for C. perfrin-
gens. Prevalence data for Clostridia spp. based on age
are presented in Table 3.
Neither treatment (P = 0.23) nor age (P = 0.35) had
a signiﬁcant eﬀect on prevalence of C. perfringens shed-
ding. The factor farm/year (P = 0.08) was retained in
Fig 1. Proportional incidence of diarrhea, soft feces, and diarrhea
in need of veterinary intervention, compared between 36 probiotic-
and 36 placebo-treated foals in a 4-week randomized, blinded ﬁeld
trial. The solid bars represent the percentage of probiotic-treated
foals, the striped bars represent the percentage of placebo-treated
foals that developed the speciﬁed outcome. *Designates a signiﬁcant
diﬀerence between placebo- and probiotic-treated foals (P = 0.007)
Fig 3. Duration of diarrhea and soft feces in 36 placebo- and 36
probiotic-treated foals are shown. Mean and standard deviation
are shown. There was no signiﬁcant eﬀect of treatment on dura-
tion of either soft feces or diarrhea.
Fig 2. Incidence of diarrhea, soft feces, and diarrhea in need for
veterinary intervention compared between 36 placebo- and 36
probiotic-treated foals based on age group in a randomized, blinded
ﬁeld trial. The solid bars represent the percentage of probiotic-
treated foals, the striped bars represent the percentage of placebo-
treated foals that developed the speciﬁed outcome. Red bars
represent foals that had diarrhea, blue bars represent foals with soft
feces and orange bars represent foals with diarrhea requiring treat-
ment. Age group had a signiﬁcant eﬀect on diarrhea (P < 0.001)
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the model. Odds ratios and conﬁdence intervals are
presented in Table 1. Clostridium diﬃcile shedding
decreased over time (Fig. 4). The prevalence was too
low for statistical comparisons. Please see the support-
ing document for results of the clostridial typing
(Appendix S1).
Association of Culture Status and Presence of
Diarrhea
Fecal consistency could only be determined for the
131 of 178 (74%) fecal samples taken during the 4-week
monitoring period. Thirty-nine of 131 (30%) times the
foals had diarrhea when sampling occurred, of which 22
(56%) were C. perfringens positive. There was no statis-
tically signiﬁcant correlation of having diarrhea and a
C. perfringens positive fecal culture (r2 = 0.007,
P = 0.13). Clostridium perfringens Type C was isolated
from 4 samples, 2 of 4 (50%) were taken when the foals
had clinical signs of soft feces, 1 (25%) was taken from a
foal without clinical signs. The remaining isolate (25%)
was taken after the monitoring period had ended;
therefore, the fecal consistency was unknown. The
3 C. perfringens strains containing the gene coding for
Table 1. Odds ratios, conﬁdence intervals, and P values from selected outcomes of a randomized, placebo-con-
trolled ﬁeld trial in neonatal foals as determined by generalized linear mixed model analysis.
Outcome Variable
Relationship Between
Variables Odds Ratio Conﬁdence Interval P-Value
Diarrhea Sex Female/Male 2.12 0.04–1.54 0.06
Treatment Control/Probiotic 0.71 0.35–1.48 0.37
Age group 1/2 2.06 1.24–3.44 0.005
1/3 7.81 4.01–15.20 <0.001
1/4 43.34 13.90–135.04 <0.001
2/3 3.78 2.11–7.76 <0.001
2/4 20.99 7.25–60.75 <0.001
3/4 5.56 2.08–14.80 <0.001
Soft feces Sex Not included in ﬁnal model
Treatment Control/Probiotic 1.19 0.56–2.37 0.62
Age group 1/2 2.49 1.40–4.43 0.002
1/3 4.25 2.26–8.02 <0.001
1/4 34.12 12.21–95.31 <0.001
2/3 1.70 0.95–3.03 0.007
2/4 13.66 5.43–34.36 0.07
3/4 8.01 3.33–19.24 <0.001
Diarrhea and treatment Sex Not included in ﬁnal model
Treatment Control/Probiotic 0.35 0.16–0.75 0.007
Age group 1/2 3.46 1.85–6.46 <0.001
1/3 10.76 4.26–27.20 <0.001
1/4 25.75 7.63–86.86 <0.001
2/3 3.10 1.33–7.22 0.008
2/4 7.43 2.25–24.48 0.001
3/4 2.39 2.39–0.79 0.12
Clostridium perfringens
shedding
Sex Not included in ﬁnal model
Treatment Control/Probiotic 0.65 0.32–1.31 0.23
Age at fecal sampling
(weeks)
0–2/2–4 1.15 0.58–2.26 0.68
0–2/4–6 1.75 0.80–3.80 0.15
2–4/4–6 1.52 0.72–3.20 0.27
1, age group 0–7 days; 2, age group 8–14 days; 3, age group 15–21 days; 4, age group 22–28 days.
Table 2. Longitudinal fecal shedding of Clostridium diﬃcile and Clostridium perfringens of foals treated with
placebo or a probiotic formulation for 3 weeks.
Age at Fecal
Sampling (weeks) Overall Probiotic Placebo
C. diﬃcile 0–2 8/71 (11%) 5/35 (14%) 3/36 (8%)
2–4 10/60 (17%) 5/30 (17%) 5/30 (17)%
4–6 2/47 (4%) 1/22 (5%) 1/25 (4%)
Overall 20/178 (11%) 11/87 (13%) 9/91 (10%)
C. perfringens 0–2 43/71 (61%) 24/35 (69%) 19/36 (53%)
2–4 34/60 (57%) 17/30 (57%) 17/30 (57)%
4–6 21/47 (45%) 10/22 (46%) 11/25 (44%)
Overall 98/178 (55%) 51/87 (59%) 47/91 (52%)
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beta2 toxin (cpb2) were isolated from foals with normal
feces. Five of 39 (13%) diarrheic samples were C. diﬃ-
cile positive. There was no statistically signiﬁcant corre-
lation between the presence of clinical signs and
C. diﬃcile-positive fecal culture result (r2 = 0.0012,
P = 0.13).
Quality Control of Probiotics
The placebo sachets yielded no bacterial growth.
The probiotic sachets yielded between 3–4 9 103
colony-forming units Lactobacillus spp. colonies and
1.3–4.2 9 103  104 Biﬁdobacterium spp. colonies.
Discussion
This study showed that a 3-week course of prophylac-
tic probiotic treatment did not reduce the incidence or
duration of diarrhea in neonatal foals and could have
even contributed to foals developing more severe disease.
The probiotic strains were selected for their in vitro abil-
ity to inhibit pathogens; however, there was no eﬀect on
fecal shedding of C. perfringens in vivo. The cumulative
prevalence of C. diﬃcile and C. perfringens fecal shed-
ding in healthy foals was similar to previous reports.
Probiotics have been shown to be unable to colonize
the gastrointestinal tract of horses and it is therefore
unlikely that they can act beyond their period of admin-
istration.7,10 The 1 week of treatment course chosen in
previous studies therefore might not be suﬃcient to see
an eﬀect.3,5,9 A treatment period of 3 weeks was chosen
for this study. The lack of a beneﬁcial eﬀect of probiot-
ic treatment, despite the longer administration period,
during the time of highest diarrhea incidence between 8
and 15 days, is disappointing and raises further concern
about their potential eﬃcacy. In 1 previous study, a
multistrain probiotic product derived from equine
gastrointestinal contents was studied in a 1-week
randomized, placebo-controlled, double-blinded clinical
trial. Foals in the probiotic group showed statistically
signiﬁcant larger weight gain after treatment and a sig-
niﬁcantly lower incidence of diarrhea.9 These eﬀects,
however, were only signiﬁcant at one time point
(2–3 weeks of age), which was after probiotic adminis-
tration had ceased and the relevance of a single period
of increased weight gain, with no discernable clinical
impact, is debatable. In another randomized, placebo-
controlled clinical trial, assessing an equine-derived
strain of Lactobacillus pentosus, probiotic administration
was associated with a signiﬁcantly higher incidence of
diarrhea, presence of clinical and the need for veterinary
examination and treatment.3 In that study, an equine-
derived strain was chosen as probiotic and the authors
postulated that the increased incidence of severe diarrhea
seen could have been caused by excessive organic acid
(eg, lactic acid) production by overgrowing lactobacilli
in the relatively poorly developed neonatal intestinal
microbiota.3 As this probiotic led to an increased inci-
dence of diarrhea, we chose to evaluate probiotic strains
used for human probiotic formulations and with in vitro
evidence for inhibitory activity against C. diﬃcile and
C. perfringens.12 The reasons for the increased incidence
of diarrhea requiring treatment in our study are unclear,
but could also relate to an increase in lactic acid-
producing bacteria. C. perfringens did not appear to be
involved in pathogenesis of the diarrhea as shedding
rates of C. perfringens were not signiﬁcantly diﬀerent
between the treatment and placebo groups.
Probiotic treatment decreased incidence of diarrhea
by 45% in a study where 130 healthy neonatal foals
were administered probiotics once a week for up to
20 weeks.5 The evidence for a beneﬁcial eﬀect should
however be considered weak, as the study had several
limitations, including lack of blinding. It is further
unclear how randomization and monitoring of the foals
was performed and why an unequally sized control
group was used. Quality control of the administered
probiotic was also not performed.
The probiotic was designed to contain 1 9 107–9 bac-
terial colonies per 2 g. Only 3–4 9 103–4 of bacteria per
2 g were grown when the probiotics were assessed for
content. The testing was performed 18 months after the
manufacturing date but within the expiry date. While
this is disappointing, it has been shown before that
many veterinary and human probiotic preparations are
not being accurately represented by label claims.15 It is
arguable that the lack of a positive eﬀect in this study
could be because of an inadequate dose; however, pres-
ence of a signiﬁcantly higher incidence of diarrhea
requiring veterinary treatment in the probiotic group
suggests that there was an eﬀect of the probiotic, albeit
an undesirable one.
There was no impact of treatment on shedding of
C. diﬃcile and C. perfringens. However, data obtained
here provide more insight into the epidemiology of
these potentially important pathogens in foals. A previ-
ous study of C. diﬃcile reported isolation of the bacte-
rium from 30% of foals shortly after birth, decreasing
to 3% by 4 weeks of age and 0% at 6 weeks.16
Fig 4. Longitudinal prevalence of fecal shedding of Clostridium
perfringens and C. diﬃcile in a randomized, placebo-controlled
ﬁeld trial in neonatal foals. The solid bars represent the percentage
of probiotic-treated foals, the striped bars represent the percentage
of placebo-treated foals that were shedding either C. diﬃcile or
C. perfringens. The green bars represent data for C. perfringens;
the gray bars represent data for C. diﬃcile.
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Similarly in this study, initial prevalence in the ﬁrst
2 weeks after birth was 17% and decreased to 13% at
4 weeks and was 0% at 6 weeks of age. A high preva-
lence of C. diﬃcile colonization in healthy neonates fol-
lowed by a rapid decline as the animal (and its
microbiota) matures has also been reported in other
species.17 As the prevalence dropped to <1% at 4–
6 weeks of age, this approaches prevalence of 0–8% in
most studies of healthy adult horses.14,16,18–20
The prevalence of 57% for fecal shedding of
C. perfringens is similar to a previous study where a
prevalence of 62% in 0- to 2-month-old foals was
reported.21 Unlike with C. diﬃcile, the prevalence did
not decrease substantially at 6 weeks of age, which is
consistent with a previous study where prevalence rates
remained at 30% at 1–2 months of age.21 Clostridium
perfringens shedding in healthy adults other than
broodmares is uncommon, with most studies reporting
rates <1%,14,22–24 so further studies are needed to
determine when prevalence of C. perfringens shedding
decreases.
The lack of eﬀect of the probiotic formulation on
C. diﬃcile and C. perfringens shedding in the current
study is disappointing given the in vitro inhibitory
activity against these pathogens.12 In vitro results can-
not necessarily be extrapolated to in vivo conditions, as
was evident here. In vitro testing should be performed
to detect potential beneﬁcial and harmful eﬀects, but
eﬀects need to be conﬁrmed in randomized, placebo-
controlled clinical trials. The eﬀect of probiotics to
decrease shedding of C. diﬃcile and C. perfringens has
not been studied in animals previously, but 2 studies
have been performed to evaluate the eﬀects of probiot-
ics on Salmonella shedding. In 1 study assessing probi-
otic administration in the postoperative period after
colic surgery, no diﬀerence in Salmonella shedding rates
was seen between groups.25 In a second study, 5-day
administration of probiotics to horses with colic did not
result in signiﬁcantly reduced shedding rates of Salmo-
nella.26 Please see the supporting document for discus-
sion of the clostridial types.
There were several limitations to this study. Because
of the low number of foals born in that remaining foal-
ing season, the study period was extended to the follow-
ing breeding season. The factor farm/year had to be
retained in most statistical models, indicating that a
higher number of farms should have been included to
decrease the inﬂuence of this factor. The selection of
farms was made based on location for the convenience
of sampling. We could not determine whether foals had
other clinical signs at the time of diarrhea as these were
recorded inconsistently and were removed from analy-
sis. The farm veterinarians made the decision to treat a
foal and reasons for this decision were not recorded.
The sample size at the end of the study was smaller
than initially calculated because of unforeseen circum-
stances. It was elected not to extend the study period
further as preliminary statistical analysis showed no
evidence of a trend toward eﬃcacy, and a negative
impact on what is perhaps the most important clinical
outcome, requirement of veterinary treatment.
Probiotics are often approached by owners and veter-
inarians with the thought that they will at worst be inef-
fective, something that might not be true. Results of
this study do not indicate that the concept of probiotic
treatment is futile in prevention of neonatal diarrhea.
Yet, these results, combined with those of another
study3 that identiﬁed a negative impact of probiotics in
neonatal foals raise concerns. Selected probiotics have
been shown to be eﬀective for some gastrointestinal dis-
orders in humans and domestic animals yet prevention
of neonatal diarrhea has not been reported.27,28 Fur-
ther, successful probiotic studies have often involved
inﬂammatory, not infectious, disorders,29,30 raising
questions of the potential eﬃcacy of probiotics in foals
given the pathophysiology of foal diarrhea. Recent
advances in the knowledge of the equine intestinal mic-
robiota could be used to design equine-speciﬁc probiot-
ics and further investigation of this area is required.
This study, though, suggests that commercial products
that lack published safety and eﬃcacy data should be
approached with caution.
Footnotes
a Insta Gene Matrix, Bio-Rad, Mississauga, ON, Canada
b Proc GLIMMIX, SAS 9.2
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